Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | Meta-analysis: anti-BCMA CAR-T in R/R multiple myeloma

Nico Gagelmann • 26 Aug 2020
EBMT 2020
Multiple Myeloma CAR-T

Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the results from a meta-analysis evaluating the outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nico Gagelmann

The efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed myeloma after CAR-T
0:52
The efficacy of bispecific antibodies targeting BCMA or GPRC5D in relapsed myeloma after CAR-T
Nico Gagelmann • 7 Feb 2025
Investigating the outcomes and cellular dynamics of cilta-cel versus ide-cel in R/R myeloma
1:04
Investigating the outcomes and cellular dynamics of cilta-cel versus ide-cel in R/R myeloma
Nico Gagelmann • 7 Feb 2025
Addressing equity and equality in access to CAR-T in Europe
1:08
Addressing equity and equality in access to CAR-T in Europe
Nico Gagelmann • 7 Feb 2025
How CAR-T will impact the future of myeloma treatment
0:52
How CAR-T will impact the future of myeloma treatment
Nico Gagelmann • 15 Feb 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Nico Gagelmann • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Nico Gagelmann • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Nico Gagelmann • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Nico Gagelmann • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals